Macrophage infiltration promotes regrowth in MYCN-amplified neuroblastoma after chemotherapy

References

• Maris JM. Recent advances in neuroblastoma. N Engl J Med. 2010;362(23):2202–10. doi:10.1056/NEJMra0804577.
   PubMed Web of Science ®Google Scholar
• Park JR, Eggert A, Caron H. Neuroblastoma: biology, prognosis, and treatment. Hematol Oncol Clin North Am. 2010;24:65–86.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654.
   PubMed Web of Science ®Google Scholar
• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3:203–216.
   PubMed Web of Science ®Google Scholar
• Borriello L, Seeger RC, Asgharzadeh S, DeClerck YA. More than the genes, the tumor microenvironment in neuroblastoma. Cancer Lett. 2016;380:304–314.
   PubMed Web of Science ®Google Scholar
• Colon NC, Chung DH. Neuroblastoma. Adv Pediatr. 2011;58:297–311.
   PubMedGoogle Scholar
• Cohn SL, Pearson AD, London WB, Monclair T, Ambros APF, PF BGM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J Clin Oncol. 2009;27(2):289–297.
   PubMed Web of Science ®Google Scholar
• Campbell K, Gastier-Foster JM, Mann M, Naranjo AH, Van Ryn C, Bagatell R, Matthay KK, London WB, Irwin MS, Shimada H, et al. Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children’s Oncology Group. Cancer. 2017;123(21):4224–4235. doi:10.1002/cncr.30873.
   PubMed Web of Science ®Google Scholar
• Rickman DS, Schulte JH, Eilers M. The Expanding World of N-MYC-Driven Tumors. Cancer Discov. 2018;8:150–163.
   PubMed Web of Science ®Google Scholar
• Otte J, Dyberg C, Pepich A, Johnsen JI. MYCN Function in Neuroblastoma Development. Front Oncol. 2020;10:624079. doi:10.3389/fonc.2020.624079.
   PubMed Web of Science ®Google Scholar
• Brandetti E, Veneziani I, Melaiu O, Pezzolo A, Castellano A, Boldrini R, Ferretti E, Fruci D, Moretta L, Pistoia V, et al. MYCN is an immunosuppressive oncogene dampening the expression of ligands for NK-cell-activating receptors in human high-risk neuroblastoma. Oncoimmunology. 2017;6(6):e1316439. doi:10.1080/2162402X.2017.1316439.
   PubMed Web of Science ®Google Scholar
• Sugio K, Nakagawara A, Sasazuki T. Association of expression between N-myc gene and major histocompatibility complex class I gene in surgically resected human neuroblastoma. Cancer. 1991;67(5):1384–1388. doi:10.1002/1097-0142(19910301)67:5<1384::AID-CNCR2820670518>3.0.CO;2-7.
   PubMed Web of Science ®Google Scholar
• Raieli S, Di Renzo D, Lampis S, Amadesi C, Montemurro L, Pession A, Hrelia P, Fischer M, Tonelli R. MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma. Front Oncol. 2021;11:625207. doi:10.3389/fonc.2021.625207.
   PubMed Web of Science ®Google Scholar
• Hashimoto O, Yoshida M, Koma Y, Yanai T, Hasegawa D, Kosaka Y, Nishimura N, Yokozaki H. Collaboration of cancer-associated fibroblasts and tumour-associated macrophages for neuroblastoma development. J Pathol. 2016;240(2):211–223. doi:10.1002/path.4769.
   PubMed Web of Science ®Google Scholar
• Peinemann F, Tushabe DA, van Dalen EC, Berthold F. Rapid COJEC versus standard induction therapies for high-risk neuroblastoma. Cochrane Database Syst Rev. 2015;5:CD010774. doi:10.1002/14651858.CD010774.pub2.
   PubMed Web of Science ®Google Scholar
• Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer. 2013;13(10):714–726. doi:10.1038/nrc3599.
   PubMed Web of Science ®Google Scholar
• van Groningen T, Koster J, Valentijn LJ, Zwijnenburg DA, Akogul N, Hasselt NE, Broekmans M, Haneveld F, Nowakowska NE, Bras J, et al. Neuroblastoma is composed of two super-enhancer-associated differentiation states. Nat Genet. 2017;49(8):1261–1266. doi:10.1038/ng.3899.
   PubMed Web of Science ®Google Scholar
• Boeva V, Louis-Brennetot C, Peltier A, Durand S, Pierre-Eugene C, Raynal V, Etchevers HC, Thomas S, Lermine A, Daudigeos-Dubus E, et al. Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries. Nat Genet. 2017;49(9):1408–1413.
   PubMed Web of Science ®Google Scholar
• Gartlgruber M, Sharma AK, Quintero A, Dreidax D, Jansky S, Park YG, Kreth S, Meder J, Doncevic D, Saary P, et al. Super enhancers define regulatory subtypes and cell identity in neuroblastoma. Nat Cancer. 2021;2(1):114–128.
   PubMedGoogle Scholar
• Karlsson J, Valind A, Holmquist Mengelbier L, Bredin S, Cornmark L, Jansson C, Wali A, Staaf J, Viklund B, Øra I, et al. Four evolutionary trajectories underlie genetic intratumoral variation in childhood cancer. Nat Genet. 2018;50(7):944–950. doi:10.1038/s41588-018-0131-y.
   PubMed Web of Science ®Google Scholar
• Andersson N, Bakker B, Karlsson J, Valind A, Holmquist Mengelbier L, Spierings DCJ, Foijer F, Gisselsson D. Extensive Clonal Branching Shapes the Evolutionary History of High-Risk Pediatric Cancers. Cancer Res. 2020;80(7):1512–1523. doi:10.1158/0008-5472.CAN-19-3468.
   PubMed Web of Science ®Google Scholar
• Eleveld TF, Oldridge DA, Bernard V, Koster J, Colmet Daage L, Diskin SJ, Schild L, Bentahar NB, Bellini A, Chicard M, et al. Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations. Nat Genet. 2015;47(8):864–871. doi:10.1038/ng.3333.
   PubMed Web of Science ®Google Scholar
• Schleiermacher G, Javanmardi N, Bernard V, Leroy Q, Cappo J, Rio Frio T, Pierron G, Lapouble E, Combaret V, Speleman F, et al. Emergence of New ALK Mutations at Relapse of Neuroblastoma. J Clin Oncol. 2014;32(25):2727–2734. doi:10.1200/JCO.2013.54.0674.
   PubMed Web of Science ®Google Scholar
• Schramm A, Koster J, Assenov Y, Althoff K, Peifer M, Mahlow E, Odersky A, Beisser D, Ernst C, Henssen AG, et al. Mutational dynamics between primary and relapse neuroblastomas. Nat Genet. 2015;47(8):872–877. doi:10.1038/ng.3349.
   PubMed Web of Science ®Google Scholar
• McGranahan N, Clonal Heterogeneity SC. Tumor Evolution: Past, Present, and the Future. Cell. 2017;168(4):613–628. doi:10.1016/j.cell.2017.01.018.
   PubMed Web of Science ®Google Scholar
• Smith MP, Sanchez-Laorden B, O’Brien K, Brunton H, Ferguson J, Young H, Dhomen N, Flaherty KT, Frederick DT, Cooper ZA, et al. The immune microenvironment confers resistance to MAPK pathway inhibitors through macrophage-derived TNFalpha. Cancer Discov. 2014;4(10):1214–1229. doi:10.1158/2159-8290.CD-13-1007.
   PubMed Web of Science ®Google Scholar
• Beechem JM. High-Plex Spatially Resolved RNA and Protein Detection Using Digital Spatial Profiling: A Technology Designed for Immuno-oncology Biomarker Discovery and Translational Research. Methods Mol Biol. 2020;2055:563–583.
   PubMedGoogle Scholar
• Merritt CR, Ong GT, Church SE, Barker K, Danaher P, Geiss G, Hoang M, Jung J, Liang Y, McKay-Fleisch J, et al. Multiplex digital spatial profiling of proteins and RNA in fixed tissue. Nat Biotechnol. 2020;38(5):586–599. doi:10.1038/s41587-020-0472-9.
   PubMed Web of Science ®Google Scholar
• Wolf Y, Anderson AC, Kuchroo VK. TIM3 comes of age as an inhibitory receptor. Nat Rev Immunol. 2020;20(3):173–185. doi:10.1038/s41577-019-0224-6.
   PubMed Web of Science ®Google Scholar
• Miyamoto T, Murakami R, Hamanishi J, Tanigaki K, Hosoe Y, Mise N, Takamatsu S, Mise Y, Ukita M, Taki M, et al. B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression. Cancer Immunol Res. 2022;10(1):56–69. doi:10.1158/2326-6066.CIR-21-0407.
   PubMed Web of Science ®Google Scholar
• Komohara Y, Jinushi M, Takeya M. Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci. 2014;105(1):1–8. doi:10.1111/cas.12314.
   PubMed Web of Science ®Google Scholar
• Buechler C, Ritter M, Orso E, Langmann T, Klucken J, Schmitz G. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol. 2000;67(1):97–103. doi:10.1002/jlb.67.1.97.
   PubMed Web of Science ®Google Scholar
• Deshmane SL, Kremlev S, Amini S, Sawaya BE. Monocyte chemoattractant protein-1 (MCP-1): an overview. J Interferon Cytokine Res. 2009;29(6):313–326. doi:10.1089/jir.2008.0027.
   PubMed Web of Science ®Google Scholar
• Pierce JH, Di Marco E, Cox GW, Lombardi D, Ruggiero M, Varesio L, Wang LM, Choudhury GG, Sakaguchi AY, Di Fiore PP, et al. Macrophage-colony-stimulating factor (CSF-1) induces proliferation, chemotaxis, and reversible monocytic differentiation in myeloid progenitor cells transfected with the human c-fms/CSF-1 receptor cDNA. Proc Natl Acad Sci U S A. 1990;87(15):5613–5617. doi:10.1073/pnas.87.15.5613.
   PubMed Web of Science ®Google Scholar
• Cassetta L, Targeting Tumor-Associated KT. Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors. Front Cell Dev Biol. 2018;6:38. doi:10.3389/fcell.2018.00038.
   PubMed Web of Science ®Google Scholar
• Manas A, Aaltonen K, Andersson N, Hansson K, Adamska A, Seger A, Yasui H, van den Bos H, Radke K, Esfandyari J, et al. Clinically relevant treatment of PDX models reveals patterns of neuroblastoma chemoresistance. Sci Adv. 2022;8(43):eabq4617. doi:10.1126/sciadv.abq4617.
   PubMed Web of Science ®Google Scholar
• Sengupta S, Das S, Crespo A, Miller B, Sharma B, Shupei Z, Dries R, Huang H, Krajewska M, Debruyne DN, et al. Cell lineage as a predictor of immune response in neuroblastoma. bioRxiv preprint. 2021. doi:10.1101/2021.01.29.428154.
   Google Scholar
• Verhoeven BM, Mei S, Olsen TK, Gustafsson K, Valind A, Lindstrom A, Gisselsson D, Fard SS, Hagerling C, Kharchenko PV, et al. The immune cell atlas of human neuroblastoma. Cell Rep Med. 2022;Jun 21;3(6):100657. doi:10.1016/j.xcrm.2022.100657.
   Google Scholar
• Braekeveldt N, Wigerup C, Tadeo I, Beckman S, Sanden C, Jonsson J, Erjefält JS, Berbegall AP, Börjesson A, Backman T, et al. Neuroblastoma patient-derived orthotopic xenografts reflect the microenvironmental hallmarks of aggressive patient tumours. Cancer Lett. 2016;375(2):384–389. doi:10.1016/j.canlet.2016.02.046.
   PubMed Web of Science ®Google Scholar
• Bauche D, Joyce-Shaikh B, Jain R, Grein J, Ku KS, Blumenschein WM, Ganal-Vonarburg SC, Wilson DC, McClanahan TK, de Waal Malefyt R, et al. LAG3(+) Regulatory T Cells Restrain Interleukin-23-Producing CX3CR1(+) Gut-Resident Macrophages during Group 3 Innate Lymphoid Cell-Driven Colitis. Immunity. 2018;49(2):342–352. e5.
   PubMed Web of Science ®Google Scholar
• Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495–499.
   PubMed Web of Science ®Google Scholar
• Szanto CL, Cornel AM, Tamminga SM, Delemarre EM, de Koning CCH, van den Beemt D, Dunnebach E, Tas ML, Dierselhuis MP, Tytgat LGAM, et al. Immune Monitoring during Therapy Reveals Activitory and Regulatory Immune Responses in High-Risk Neuroblastoma. Cancers (Basel). 2021;13(9):9. doi:10.3390/cancers13092096.
   Web of Science ®Google Scholar
• Wei JS, Kuznetsov IB, Zhang S, Song YK, Asgharzadeh S, Sindiri S, Wen X, Patidar R, Najaraj S, Walton A, et al. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma. Clin Cancer Res. 2018;24(22):5673–5684.
   PubMed Web of Science ®Google Scholar
• Zhang P, Wu X, Basu M, Dong C, Zheng P, Liu Y, Sandlar AD. MYCN Amplification Is Associated with Repressed Cellular Immunity in Neuroblastoma: An In Silico Immunological Analysis of TARGET Database. Front Immunol. 2017;8:1473.
   PubMed Web of Science ®Google Scholar
• Mao Y, Eissler N, Blanc KL, Johnsen JI, Kogner P, Kiessling R. Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma. Clin Cancer Res. 2016;22:3849–3859.
   PubMed Web of Science ®Google Scholar
• Mina M, Boldrini R, Citti A, Romania P, D’Alicandro V, De IM. Tumor-infiltrating T lymphocytes improve clinical outcome of therapy-resistant neuroblastoma. Oncoimmunology. 2015;4:e1019981.
   PubMed Web of Science ®Google Scholar
• Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263–266.
   PubMed Web of Science ®Google Scholar
• Song L, Ara T, Wu HW, Woo CW, Reynolds CP, Seeger RC, DeClerck YA, Thiele CJ, Sposto R, Metelitsa LS. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma. J Clin Invest. 2007;117(9):2702–2712.
   PubMed Web of Science ®Google Scholar
• Marrano P, Irwin MS, Thorner PS. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis. Genes Chromosomes Cancer. 2017;56:28–41.
   PubMed Web of Science ®Google Scholar
• Webb MW, Sun J, Sheard MA, Liu WY, Wu HW, Jackson JR, Malvar J, Sposto R, Daniel D, Seeger RC C olony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytes. Int J Cancer. 2018;143(6):1483–1493. doi:10.1002/ijc.31532.
   PubMed Web of Science ®Google Scholar
• Pyonteck SM, Akkari L, Schuhmacher AJ, Bowman RL, Sevenich L, Quail DF, Olson OC, Quick ML, Huse JT, Teijeiro V, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med. 2013;19(10):1264–1272.
   PubMed Web of Science ®Google Scholar
• Asgharzadeh S, Salo JA, Ji L, Oberthuer A, Fischer M, Berthold F, Hadjidaniel M, Liu CWY, Metelitsa LS, Pique-Regi R, et al. Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma. J Clin Oncol. 2012;30(28):3525–3532. doi:10.1200/JCO.2011.40.9169.
   PubMed Web of Science ®Google Scholar